These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 18759257

  • 1. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
    Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2008 Sep 15; 59(9):1270-8. PubMed ID: 18759257
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2005 Feb 15; 52(2):582-91. PubMed ID: 15692973
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD, Maksymowych WP, CANDLE Study Group.
    J Rheumatol; 2010 Jun 15; 37(6):1203-10. PubMed ID: 20231198
    [Abstract] [Full Text] [Related]

  • 4. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation.
    Li EK, Griffith JF, Lee VW, Wang YX, Li TK, Lee KK, Tam LS.
    Rheumatology (Oxford); 2008 Sep 15; 47(9):1358-63. PubMed ID: 18573802
    [Abstract] [Full Text] [Related]

  • 5. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J.
    Arthritis Rheum; 2003 Aug 15; 48(8):2224-33. PubMed ID: 12905476
    [Abstract] [Full Text] [Related]

  • 6. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May 15; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, ATLAS Study Group.
    Arthritis Rheum; 2006 Jul 15; 54(7):2136-46. PubMed ID: 16802350
    [Abstract] [Full Text] [Related]

  • 8. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
    Braun J, van der Heijde D, Doyle MK, Han C, Deodhar A, Inman R, de Vlam K, Burmester GR, Van den Bosch F, Xu S, Visvanathan S, Rahman MU.
    Arthritis Rheum; 2009 Aug 15; 61(8):1032-6. PubMed ID: 19644896
    [Abstract] [Full Text] [Related]

  • 9. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
    Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D.
    Arthritis Rheum; 2003 Apr 15; 48(4):1126-36. PubMed ID: 12687557
    [Abstract] [Full Text] [Related]

  • 10. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2005 Feb 15; 64(2):229-34. PubMed ID: 15388511
    [Abstract] [Full Text] [Related]

  • 11. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'connor P, Tan AL, Conaghan PG, Greenstein A, Emery P.
    Ann Rheum Dis; 2005 Nov 15; 64(11):1568-75. PubMed ID: 15829577
    [Abstract] [Full Text] [Related]

  • 12. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group.
    Arthritis Rheum; 2003 Nov 15; 48(11):3230-6. PubMed ID: 14613288
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial.
    Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Muñoz-Valle JF, Gamez-Nava JI.
    J Rheumatol; 2004 Aug 15; 31(8):1568-74. PubMed ID: 15290737
    [Abstract] [Full Text] [Related]

  • 14. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2008 Mar 15; 67(3):340-5. PubMed ID: 17967831
    [Abstract] [Full Text] [Related]

  • 15. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J.
    Arthritis Rheum; 2010 May 15; 62(5):1290-7. PubMed ID: 20461780
    [Abstract] [Full Text] [Related]

  • 16. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun 15; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 17. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
    Keeling S, Oswald A, Russell AS, Maksymowych WP.
    J Rheumatol; 2006 Mar 15; 33(3):558-61. PubMed ID: 16463437
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E, Giménez MD, Mayordomo L, Rodríguez S, González MP, Marenco JL.
    Scand J Rheumatol; 2004 Mar 15; 33(5):323-6. PubMed ID: 15513681
    [Abstract] [Full Text] [Related]

  • 19. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, Bala M, Han J, Braun J.
    Arthritis Rheum; 2006 Aug 15; 55(4):569-74. PubMed ID: 16874778
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH.
    Ann Rheum Dis; 2008 Mar 15; 67(3):346-52. PubMed ID: 17967833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.